Contacts

Yanhong Deng, M.D.

CONTACT

+86-13925106525 13925106525@163.com

Qin Zheng

CONTACT

Sponsors

Lead Sponsor

Sun Yat-sen University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Willing and able to provide written informed consent.
•2. Histological or cytological documentation of adenocarcinoma of the colon or rectum.
•3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
•4. Tumor tissues were identified as mismatch repair-deficient (dMMR) by immunohistochemistry (IHC) method or microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR).
•5. Subjects with stage IV colorectal cancer must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.
•6. Previous treatment with an anti-PD-1 or PD-L1 monoclonal antibody for advanced or metastatic colorectal cancer has failed. Treatment failure was defined as: disease progression or unacceptable toxicity during treatment or within 6 months after the last treatment.
•7. Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.

Exclusion Criteria

•1. Previously received anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T-lymphocyte-associated Protein 4, CTLA-4) antibody.
•2. Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment.
•3. Heart failure grade III/IV (NYHA-classification).
•4. Unresolved toxicity higher than CTCAE v.5.0 Grade 1 attributed to any prior therapy/procedure.
•5. Subjects with known allergy to the study drugs or to any of its excipients.
•6. Current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
•7. Breast- feeding or pregnant women.
•8. Lack of effective contraception.

Related studies

RECRUITINGPhase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721 · Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

RECRUITING

Early Onset Colorectal Cancer Detection

NCT06342401 · Colorectal Cancer, Colorectal Neoplasms, and more

RECRUITINGEARLY Phase 1

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

NCT07328087 · Colorectal Cancer Metastatic, Colorectal Cancer Stage III, and more

RECRUITINGEARLY Phase 1

A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer

NCT07050394 · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent, and more

RECRUITINGPhase 3

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

NCT06762405 · Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

View all related studies →

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Early Onset Colorectal Cancer Detection

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Trial snapshot

Condition

Locations shown

For caregivers